Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 03, 2015 11:33 AM ET


Company Overview of Jubilant Cadista Pharmaceuticals Inc.

Company Overview

Jubilant Cadista Pharmaceuticals Inc. discovers, develops, manufactures, and distributes prescription generic pharmaceutical products to customers in the United States. It offers anti-hypertensive, diuretic, and andrenocortical steroid tablets and capsules. The company’s generic products include alendronate sodium, cyclobenzaprine HCL, donepezil, escitalopram, hydrochlorothiazide, lamotrigine, losartan HCTZ, losartan potassium, meclizine, methylprednisolone, olanzapine ODT, oxcarbazepine, pantoprazole delayed release, prednisone, prochlorperazine maleate, risperidone odt, terazosin HCL, and valacyclovir. Jubilant Cadista Pharmaceuticals Inc. was formerly known as Cadista Pharmaceuticals, Inc...

207 Kiley Drive

Salisbury, MD 21801

United States

Founded in 1991





Key Executives for Jubilant Cadista Pharmaceuticals Inc.

Chief Executive Officer, President, Director, Chief Executive Officer of Cadista Holdings Inc and President of Cadista Holdings Inc
Age: 46
Chief Financial Officer and Director
Age: 53
Chief Operations Officer
Age: 63
Senior Director of National Accounts
Director of Human Resources
Compensation as of Fiscal Year 2015.

Jubilant Cadista Pharmaceuticals Inc. Key Developments

Cadista Holdings Inc. and Jubilant Cadista Pharmaceuticals Inc. Announce Resignation of Neeraj Agrawal from their Board of Directors

Cadista Holdings Inc. announced that by letter, dated August 1, 2014, Neeraj Agrawal resigned as a member of the company's Board of Directors, and as a member of the Board of Directors of its wholly-owned subsidiary, Jubilant Cadista Pharmaceuticals Inc., in each case effective immediately following the Board of Directors meetings held on such date.

Cadista Holdings Inc. and Jubilant Cadista Pharmaceuticals Inc. Elects R. Sankaraiah to as Director of Both Companies

On July 31, 2013 the Board of Directors of Cadista Holdings Inc. and the Company's Jubilant Cadista Pharmaceuticals Inc. elected R. Sankaraiah to serve as a director of each of the Company and Cadista Pharmaceuticals. Mr. Sankaraiah, in addition to being a member of the Board of Directors, will also serve as a member of the Audit Committee of the Company and has been designated by the Board as a "financial expert" in accordance with applicable SEC regulations. Mr. Sankaraiah was previously a director of the Company and Cadista Pharmaceuticals from June 2005 until his resignation on May 4, 2012. From the time of the formation of the Company's Audit Committee in May 2011 until his resignation in May 2012, Mr. Sankaraiah was also on the Company's Audit Committee and was designated by the Board as a 'financial expert' in accordance with applicable SEC regulations.

Similar Private Companies By Industry

Company Name Region
Methapharm Inc. United States
Meridian Medical Technologies, Inc. United States
Yasoo Health Inc. United States
Searle & Co. United States
Victus, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Jubilant Cadista Pharmaceuticals Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at